BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 8110728)

  • 1. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro.
    Hank JA; Surfus J; Gan J; Chew TL; Hong R; Tans K; Reisfeld R; Seeger RC; Reynolds CP; Bauer M
    J Immunother Emphasis Tumor Immunol; 1994 Jan; 15(1):29-37. PubMed ID: 8110728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of cellular cytotoxicity and complement-mediated lysis of melanoma and neuroblastoma cells in vitro by murine antiganglioside antibodies MB 3.6 and 14.G2a.
    Mayer P; Handgretinger R; Bruchelt G; Schaber B; Rassner G; Fierlbeck G
    Melanoma Res; 1994 Apr; 4(2):101-6. PubMed ID: 8069095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.
    Frost JD; Hank JA; Reaman GH; Frierdich S; Seeger RC; Gan J; Anderson PM; Ettinger LJ; Cairo MS; Blazar BR; Krailo MD; Matthay KK; Reisfeld RA; Sondel PM
    Cancer; 1997 Jul; 80(2):317-33. PubMed ID: 9217046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model.
    Helfand SC; Soergel SA; Donner RL; Gan J; Hank JA; Lindstrom MJ; Sondel PM
    J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):188-97. PubMed ID: 7834118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma.
    Nguyen R; Moustaki A; Norrie JL; Brown S; Akers WJ; Shirinifard A; Dyer MA
    Clin Cancer Res; 2019 Dec; 25(24):7554-7564. PubMed ID: 31455682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.
    Hank JA; Robinson RR; Surfus J; Mueller BM; Reisfeld RA; Cheung NK; Sondel PM
    Cancer Res; 1990 Sep; 50(17):5234-9. PubMed ID: 2386933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.
    Nguyen R; Houston J; Chan WK; Finkelstein D; Dyer MA
    Cancer Immunol Immunother; 2018 Apr; 67(4):615-626. PubMed ID: 29327110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance.
    Tibbetts R; Yeo KK; Muthugounder S; Lee MH; Jung C; Porras-Corredor T; Sheard MA; Asgharzadeh S
    Cancer Immunol Immunother; 2022 Jan; 71(1):153-164. PubMed ID: 34043024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.
    Wu HW; Sheard MA; Malvar J; Fernandez GE; DeClerck YA; Blavier L; Shimada H; Theuer CP; Sposto R; Seeger RC
    Clin Cancer Res; 2019 Aug; 25(15):4761-4774. PubMed ID: 31068371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
    Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
    Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
    Sondel PM; Hank JA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro.
    Kawashima I; Tada N; Fujimori T; Tai T
    J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells.
    Barker E; Mueller BM; Handgretinger R; Herter M; Yu AL; Reisfeld RA
    Cancer Res; 1991 Jan; 51(1):144-9. PubMed ID: 1988079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergetic effect of interleukin-2 and cellular cytotoxicity against a novel tumor-associated carbohydrate antigen Le(a)/Le(a) (dimeric Le(a)) mediated by monoclonal antibody NCC-ST-421 in adoptive immunization using SCID mice.
    Watanabe M; Kubota T; Kitajima M; Hakomori S
    Cancer Immunol Immunother; 1993 Sep; 37(4):245-50. PubMed ID: 8348564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8.
    Zhao Q; Ahmed M; Guo HF; Cheung IY; Cheung NK
    J Biol Chem; 2015 May; 290(21):13017-27. PubMed ID: 25851904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes.
    Kushner BH; Cheung NK
    Cancer Res; 1991 Sep; 51(18):4865-70. PubMed ID: 1654202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
    Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
    Front Immunol; 2021; 12():690467. PubMed ID: 34367149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin.
    Honsik CJ; Jung G; Reisfeld RA
    Proc Natl Acad Sci U S A; 1986 Oct; 83(20):7893-7. PubMed ID: 3094017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
    Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
    Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating.
    Chen RL; Reynolds CP; Seeger RC
    Cancer Immunol Immunother; 2000 Feb; 48(11):603-12. PubMed ID: 10663607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.